Developer docs
API playgroundTry for free, no card

Search company profiles

MultiOmic Health

Full company profile

uuid0000ijq

Namestring
MultiOmic Health
Legal namestring
Multiomic Health Limited
Company typeenum
Private
Founded yearint
2021
Descriptiontext

MultiOmic Health is a London-based, privately held precision medicine discovery company founded in 2021 that applies its proprietary MOHSAIC® platform to cardio-renal-metabolic (CRM) diseases, with an initial focus on chronic kidney disease and diabetic kidney disease. The platform integrates deep longitudinal patient datasets, multi-omics data (genomics, epigenomics, transcriptomics, proteomics, metabolomics, microbiomics) up to 500 Gb per patient, AI-enabled patient stratification models, computational systems biology simulations using ordinary differential equations, and targeted wet laboratory validation to identify molecularly distinct patient endotypes and generate novel drug targets with companion diagnostics.

The company's product portfolio spans the MOHSAIC platform itself, AI-enabled Renal Endotyping and Patient-Stratifying Models (PSM) designed for SaMD and IVD deployment, Patient-Stratified Renal Drug Targets with Companion Diagnostics, and a Global CRM Patient Registry targeting over 100,000 patients by 2028. The business model is B2B enterprise value-sharing: upfront and milestone payments plus royalties from biopharma co-development and technology licensing agreements, IP out-licensing to medtech for companion diagnostics, and research service fees from collaborative R&D projects. Biopharma companies are the primary customer segment, with NHS and academic institutions serving as data and sample partners.

MultiOmic Health has raised approximately US$13 million across three funding rounds led by Fifty Years, Hoxton Ventures, and Ada Ventures, with participation from MMC Ventures, Verve Ventures, Formic Ventures, HOF Capital, and Selvedge Venture. The company has established a joint venture (RenalDevCo) with Alloy Therapeutics' 82VS studio, research collaborations with Northern Care Alliance NHS Foundation Trust, Queen's University Belfast, and Mesh Bio, and an MoU with BIO4 Campus in Serbia. It operates with a small team of approximately 10 members and no publicly disclosed revenue.

Short descriptiontext

MultiOmic Health is a London-based AI precision medicine company that uses its MOHSAIC® platform combining multi-omics data, systems biology modeling, and wet lab validation to discover patient endotypes and develop targeted therapeutics and companion diagnostics for cardio-renal-metabolic diseases.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersLondon, United Kingdom
HQ citystring
London
HQ countrystring
United Kingdom
HQ regionstring
Europe
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
AI drug discovery, precision medicine platform, multi-omics integration, biopharma partnerships, chronic kidney disease
Industry4 codes
PRIMARYHLAAANAF
Multi-Omics Precision Medicine Platforms (genomics/proteomics/metabolomics)
SECONDARYHLAGAJAD
Bioinformatics & Multi-omics Analysis Software
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Life Science Software & Informatics (LIMS/ELN/Bioinformatics)
SECONDARYHLAAAIAE
AI/ML-Enabled Biologic Discovery Platforms (computational design, in silico screening)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
SECONDARYHLAAAIAI
Target Identification & Validation Platforms (omics-driven, chemoproteomics, genetic validation)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
NAICS code2 codes
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
  • Research and Development in the Physical, Engineering, and Life Sciences54171
SIC code2 codes
  • Services-Commercial Physical & Biological Research8731
  • In Vitro & In Vivo Diagnostic Substances2835
Product category
AI Drug Discovery
Social media profiles1 record
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model3 records
1Value-Sharing Partnerships with Biopharma
TypeLicensing Royalties
Description

Upfront and contingent milestone payments plus sales royalties on marketed drugs. Partnership structures include jointly funded and co-owned drug discovery programs on new targets; technology partnering/licensing arrangements to reposition collaborator's drug assets; and in-licensing 'fallen angel' NMEs for repositioning.

multiomic.health
2Intellectual Property Licensing to Medtech
TypeLicensing Royalties
Description

Out-licensing IP to medical technology companies for developing companion diagnostic and clinical biomarker products.

multiomic.health
3Collaborative R&D Projects
TypeProfessional Services
Description

Joint projects with healthtech companies and pharma to enhance patient stratification for clinical-stage R&D programs, generating research service fees.

multiomic.health
Marketing channels7 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure
GTM typeB2B
B2B
Offering typeServices
Services
Brand1 record
1MOHSAIC
Description

AI-enabled precision medicine discovery platform combining multi-omics data analysis, computational systems biology modeling, and wet laboratory experiments to identify patient endotypes and develop precision therapeutics

multiomic.health
Core offering1 text field

MultiOmic Health develops the MOHSAIC® platform, an AI-enabled precision medicine discovery engine that integrates multi-omics data (genomics, epigenomics, transcriptomics, proteomics, metabolomics, microbiomics) with longitudinal clinical phenotyping, computational systems biology modeling, and wet laboratory validation to identify patient endotypes and discover precision therapeutic concepts. The company focuses on cardio-renal-metabolic diseases, starting with chronic kidney disease, and commercializes its outputs through biopharma partnerships, IP licensing, and collaborative R&D projects.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 3 values shown
  • Patient endotypes identified with distinct molecular signatures enabling precise disease trajectory prediction in diabetic kidney disease.
+2 more records
Product overview1 text field

MultiOmic Health operates as an AI-enabled precision medicine discovery company with the MOHSAIC® platform as its core technology foundation. The platform integrates multi-omics analysis with computational systems biology and wet laboratory experiments to identify patient endotypes and develop precision therapeutic concepts for cardio-renal-metabolic diseases. The company builds proprietary datasets through its global CRM patient registry and develops downstream products including renal endotyping models (PSM) and companion diagnostics (CDx) for patient-stratified drug targets. The portfolio spans from data-driven discovery platforms to diagnostic biomarkers, all focused on chronic kidney disease and metabolic syndrome complications.

Product and service3 records
1MOHSAIC® Platform
CategoryAI Drug Discovery Platform
Description

AI-enabled precision medicine discovery platform combining proprietary patient datasets, multi-omics data integration (genomics, epigenomics, transcriptomics, proteomics, metabolomics, microbiomics), AI/ML analytics, computational systems biology modeling, and targeted wet laboratory experiments to identify patient endotypes and discover precision therapeutic concepts for chronic multifactorial diseases. Used by biopharma, medtech, and academic collaborators.

2Renal Endotyping and Patient-Stratifying Models (PSM)
CategoryCompanion Diagnostic Products
Description

AI-enabled diagnostic models that cluster diabetic kidney disease (DKD) patients into clinical phenotypes with distinct molecular signatures, enabling prediction of disease progression trajectories at early disease stage. Designed to be optimized and implemented as SaMD (Software as a Medical Device) and IVD (In Vitro Diagnostic) products for biopharma and medtech partners.

3Patient-Stratified Renal Drug Targets with Companion Diagnostics (CDx)
CategoryPrecision Therapeutic Programs
Description

Novel drug targets identified for specific patient endotypes in kidney inflammation and fibrosis, paired with companion diagnostic biomarkers for patient selection in clinical trials. Designed to enable precision medicines with higher efficacy for specific patient subpopulations and to be out-licensed to biopharma partners for clinical development.

Scale indicator6 records

Each record includes

Type, Value, Description, Source

Partnership5 partners
1BIO4 Campus
Strategic tierMinorTypeStrategic or Co-development PartnerAnnounced on2025-09-04
Description

MoU signed to explore collaborative opportunities in biomedicine, biotechnology, and bioinformatics with strong emphasis on AI applications. Collaboration supports bioeconomy growth in Serbia.

multiomic.health
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2025-04-02
Description

MoU to jointly discover and develop first-in-class renal tissue-targeting drugs. Alloy deploys bispecific antibody and genetic medicine platforms to modulate MOH-identified drug targets. 82VS venture studio establishes 'RenalDevCo' to license IP from both parties. Both receive equity stakes, development milestone payments, and single digit royalties. MOH receives research services payments for IND-enabling studies and clinical trial management.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2024-02-07
Description

Two-year collaborative project partially funded by Innovate UK's £20M Advancing Precision Medicine programme. MultiOmic deploys MOHSAIC® platform to analyze data from NICOLA and FinnDiane cohorts for diagnostic tools in diabetic kidney disease. Aims to identify biomarkers for DKD progression and complications in specific patient subpopulations.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2022-12-06
Description

Research collaboration deploying MOHSAIC® platform on de-identified bio-samples and clinical histories from Salford Kidney Study (one of largest CKD cohorts globally) to investigate patient stratifying biomarkers in diabetic nephropathy using integrative multi-omics analyses.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2022-06-30
Description

Partnership to conduct observational clinical study on patients with chronic metabolic disease and increased CKD risk. Mesh recruits patients through healthcare provider network; MultiOmic generates multi-omics data from anonymized samples. Provides access to underrepresented Asian patient populations.

Recent move7 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Insitro combines machine learning, high-throughput biology, and human genetics to transform drug discovery. Directly comparable to MultiOmic's approach of using multi-omics data and AI to identify patient subpopulations and novel drug targets, particularly in metabolic and neurological diseases.

TypeEmerging player
Description

ProKidney is a clinical-stage biotech developing cell therapy for chronic kidney disease. Comparable therapeutic focus on CKD (MultiOmic's first indication) but uses a different modality (cell therapy vs. precision medicine/biologics) and is at later clinical stage.

TypeDirect peer
Description

Exscientia is an AI-driven precision medicine company using its proprietary platform to design and develop novel drug candidates, with patient-derived data integration. Comparable business model of using AI and patient data to enable biopharma partnerships and precision drug discovery.

TypeDirect peer
Description

Relation Therapeutics combines causal ML with multi-omics data to identify novel drug targets. Directly comparable to MultiOmic's approach of integrating multi-omics with AI to discover druggable targets, with similar disease-agnostic platform positioning.

TypeDirect peer
Description

BenevolentAI combines AI, machine learning, and biomedical knowledge graphs to accelerate drug discovery. Comparable to MultiOmic as an AI-driven drug discovery platform that identifies novel targets and partners with pharma for development.

TypeDirect peer
Description

Recursion is an AI-enabled drug discovery platform combining high-throughput biology, automated experimentation, and machine learning to identify novel therapeutic candidates. Highly comparable to MultiOmic as a techbio company building proprietary datasets and AI models to drive drug discovery, though Recursion operates at much larger scale and broader therapeutic scope.

7Tempus AI
TypeBroad incumbent
Description

Tempus is a precision medicine data and technology company combining multi-omics profiling (genomics, transcriptomics, proteomics) with AI to enable pharma R&D and clinical decision support. Comparable to MultiOmic's data integration approach but operating at much larger scale with broader offerings and an established commercial presence.

TypeDirect peer
Description

BioAge Labs is an AI-driven biotech focused on metabolic disease drug discovery, using machine learning and patient data to identify targets for age-related conditions. Closely comparable to MultiOmic in therapeutic area (metabolic disease), AI approach, and stage of development.

TypeDirect peer
Description

Owkin is an AI precision medicine company using federated learning and multi-omics analysis to identify biomarkers and develop diagnostics. Highly comparable to MultiOmic's multi-omics + AI approach to patient stratification and biomarker discovery, with similar B2B model selling into biopharma.

TypeEmerging player
Description

Cardior Pharmaceuticals develops RNA-based therapeutics for heart failure and associated cardiac diseases, with precision medicine approaches targeting specific patient subgroups. Comparable focus on cardio-renal therapeutic area and patient stratification strategies, though at later stage with clinical assets.

Market position
Weaknesses4 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile4 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI capability4 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature6 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles18 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds3 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors10 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

MultiOmic Health

AI Drug Discoverymultiomic.health

MultiOmic Health is a London-based AI precision medicine company that uses its MOHSAIC® platform combining multi-omics data, systems biology modeling, and wet lab validation to discover patient endotypes and develop targeted therapeutics and companion diagnostics for cardio-renal-metabolic diseases.

What MultiOmic Health does

MultiOmic Health is a London-based, privately held precision medicine discovery company founded in 2021 that applies its proprietary MOHSAIC® platform to cardio-renal-metabolic (CRM) diseases, with an initial focus on chronic kidney disease and diabetic kidney disease. The platform integrates deep longitudinal patient datasets, multi-omics data (genomics, epigenomics, transcriptomics, proteomics, metabolomics, microbiomics) up to 500 Gb per patient, AI-enabled patient stratification models, computational systems biology simulations using ordinary differential equations, and targeted wet laboratory validation to identify molecularly distinct patient endotypes and generate novel drug targets with companion diagnostics.

The company's product portfolio spans the MOHSAIC platform itself, AI-enabled Renal Endotyping and Patient-Stratifying Models (PSM) designed for SaMD and IVD deployment, Patient-Stratified Renal Drug Targets with Companion Diagnostics, and a Global CRM Patient Registry targeting over 100,000 patients by 2028. The business model is B2B enterprise value-sharing: upfront and milestone payments plus royalties from biopharma co-development and technology licensing agreements, IP out-licensing to medtech for companion diagnostics, and research service fees from collaborative R&D projects. Biopharma companies are the primary customer segment, with NHS and academic institutions serving as data and sample partners.

MultiOmic Health has raised approximately US$13 million across three funding rounds led by Fifty Years, Hoxton Ventures, and Ada Ventures, with participation from MMC Ventures, Verve Ventures, Formic Ventures, HOF Capital, and Selvedge Venture. The company has established a joint venture (RenalDevCo) with Alloy Therapeutics' 82VS studio, research collaborations with Northern Care Alliance NHS Foundation Trust, Queen's University Belfast, and Mesh Bio, and an MoU with BIO4 Campus in Serbia. It operates with a small team of approximately 10 members and no publicly disclosed revenue.

MultiOmic Health firmographics

Firmographics
Name
MultiOmic Health
Legal name
Multiomic Health Limited
Website
https://multiomic.health
Company type
Private
Founded year
2021
Operating status
Operating
Headcount range
11–50 employees
Short description
MultiOmic Health is a London-based AI precision medicine company that uses its MOHSAIC® platform combining multi-omics data, systems biology modeling, and wet lab validation to discover patient endotypes and develop targeted therapeutics and companion diagnostics for cardio-renal-metabolic diseases.
Ownership category
akta.pro rank

MultiOmic Health industry classification

Industry
Product category
AI Drug Discovery
NAICS
Research and Development in Biotechnology (except Nanobiotechnology) (541714), Research and Development in the Physical, Engineering, and Life Sciences (54171)
SIC
Services-Commercial Physical & Biological Research (8731), In Vitro & In Vivo Diagnostic Substances (2835)
akta.pro industry
PRIMARYHLAAANAF
Multi-Omics Precision Medicine Platforms (genomics/proteomics/metabolomics)
SECONDARYHLAGAJAD
Bioinformatics & Multi-omics Analysis Software
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Life Science Software & Informatics (LIMS/ELN/Bioinformatics)
SECONDARYHLAAAIAE
AI/ML-Enabled Biologic Discovery Platforms (computational design, in silico screening)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
SECONDARYHLAAAIAI
Target Identification & Validation Platforms (omics-driven, chemoproteomics, genetic validation)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)

Keywords

  • AI drug discovery
  • Precision medicine platform
  • Multi-omics integration
  • Biopharma partnerships
  • Chronic kidney disease

Where MultiOmic Health is headquartered

Location

Headquarters

HQ city
London
HQ country
United Kingdom
HQ region
Europe

Offices1 record

Markets served

MultiOmic Health business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure

Revenue model

  1. Value-Sharing Partnerships with Biopharma: Upfront and contingent milestone payments plus sales royalties on marketed drugs. Partnership structures include jointly funded and co-owned drug discovery programs on new targets; technology partnering/licensing arrangements to reposition collaborator's drug assets; and in-licensing 'fallen angel' NMEs for repositioning.
  2. Intellectual Property Licensing to Medtech: Out-licensing IP to medical technology companies for developing companion diagnostic and clinical biomarker products.
  3. Collaborative R&D Projects: Joint projects with healthtech companies and pharma to enhance patient stratification for clinical-stage R&D programs, generating research service fees.

Go-to-market motion2 records

Distribution channels1 record

Marketing channels7 records

MultiOmic Health product offering

Product offering

Core offering

MultiOmic Health develops the MOHSAIC® platform, an AI-enabled precision medicine discovery engine that integrates multi-omics data (genomics, epigenomics, transcriptomics, proteomics, metabolomics, microbiomics) with longitudinal clinical phenotyping, computational systems biology modeling, and wet laboratory validation to identify patient endotypes and discover precision therapeutic concepts. The company focuses on cardio-renal-metabolic diseases, starting with chronic kidney disease, and commercializes its outputs through biopharma partnerships, IP licensing, and collaborative R&D projects.

Product overview

MultiOmic Health operates as an AI-enabled precision medicine discovery company with the MOHSAIC® platform as its core technology foundation. The platform integrates multi-omics analysis with computational systems biology and wet laboratory experiments to identify patient endotypes and develop precision therapeutic concepts for cardio-renal-metabolic diseases. The company builds proprietary datasets through its global CRM patient registry and develops downstream products including renal endotyping models (PSM) and companion diagnostics (CDx) for patient-stratified drug targets. The portfolio spans from data-driven discovery platforms to diagnostic biomarkers, all focused on chronic kidney disease and metabolic syndrome complications.

Differentiator

Problem solved

Functional benefit

Brands

  • MOHSAIC: AI-enabled precision medicine discovery platform combining multi-omics data analysis, computational systems biology modeling, and wet laboratory experiments to identify patient endotypes and develop precision therapeutics

Products and services

  • MOHSAIC® Platform AI-enabled precision medicine discovery platform combining proprietary patient datasets, multi-omics data integration (genomics, epigenomics, transcriptomics, proteomics, metabolomics, microbiomics), AI/ML analytics, computational systems biology modeling, and targeted wet laboratory experiments to identify patient endotypes and discover precision therapeutic concepts for chronic multifactorial diseases. Used by biopharma, medtech, and academic collaborators.
  • Renal Endotyping and Patient-Stratifying Models (PSM) AI-enabled diagnostic models that cluster diabetic kidney disease (DKD) patients into clinical phenotypes with distinct molecular signatures, enabling prediction of disease progression trajectories at early disease stage. Designed to be optimized and implemented as SaMD (Software as a Medical Device) and IVD (In Vitro Diagnostic) products for biopharma and medtech partners.
  • Patient-Stratified Renal Drug Targets with Companion Diagnostics (CDx) Novel drug targets identified for specific patient endotypes in kidney inflammation and fibrosis, paired with companion diagnostic biomarkers for patient selection in clinical trials. Designed to enable precision medicines with higher efficacy for specific patient subpopulations and to be out-licensed to biopharma partners for clinical development.

Quantifiable outcome

  • Patient endotypes identified with distinct molecular signatures enabling precise disease trajectory prediction in diabetic kidney disease.
  • +2 more outcomes

Companies that use MultiOmic Health

Customer profile

Segments3 records

Ideal customer profiles4 records

MultiOmic Health technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

AI capability4 records

Feature6 records

MultiOmic Health partnerships and signals

Strategic signal

Partnerships

Five partnerships are on record, tiered minor and core.

  • BIO4 CampusminorStrategic or Co-development Partner · 4 September 2025MoU signed to explore collaborative opportunities in biomedicine, biotechnology, and bioinformatics with strong emphasis on AI applications. Collaboration supports bioeconomy growth in Serbia.
  • Alloy Therapeutics Inc.coreStrategic or Co-development Partner · 2 April 2025MoU to jointly discover and develop first-in-class renal tissue-targeting drugs. Alloy deploys bispecific antibody and genetic medicine platforms to modulate MOH-identified drug targets. 82VS venture studio establishes 'RenalDevCo' to license IP from both parties. Both receive equity stakes, development milestone payments, and single digit royalties. MOH receives research services payments for IND-enabling studies and clinical trial management.
  • Queen's University BelfastcoreStrategic or Co-development Partner · 7 February 2024Two-year collaborative project partially funded by Innovate UK's £20M Advancing Precision Medicine programme. MultiOmic deploys MOHSAIC® platform to analyze data from NICOLA and FinnDiane cohorts for diagnostic tools in diabetic kidney disease. Aims to identify biomarkers for DKD progression and complications in specific patient subpopulations.
  • Northern Care Alliance NHS Foundation TrustcoreStrategic or Co-development Partner · 6 December 2022Research collaboration deploying MOHSAIC® platform on de-identified bio-samples and clinical histories from Salford Kidney Study (one of largest CKD cohorts globally) to investigate patient stratifying biomarkers in diabetic nephropathy using integrative multi-omics analyses.
  • Mesh BiocoreStrategic or Co-development Partner · 30 June 2022Partnership to conduct observational clinical study on patients with chronic metabolic disease and increased CKD risk. Mesh recruits patients through healthcare provider network; MultiOmic generates multi-omics data from anonymized samples. Provides access to underrepresented Asian patient populations.

Scale indicators6 records

Recent moves7 records

Expansion highlights6 records

MultiOmic Health competitors and assessment

Company assessment

Direct peers

  • Insitro: Insitro combines machine learning, high-throughput biology, and human genetics to transform drug discovery. Directly comparable to MultiOmic's approach of using multi-omics data and AI to identify patient subpopulations and novel drug targets, particularly in metabolic and neurological diseases.
  • Exscientia: Exscientia is an AI-driven precision medicine company using its proprietary platform to design and develop novel drug candidates, with patient-derived data integration. Comparable business model of using AI and patient data to enable biopharma partnerships and precision drug discovery.
  • Relation Therapeutics: Relation Therapeutics combines causal ML with multi-omics data to identify novel drug targets. Directly comparable to MultiOmic's approach of integrating multi-omics with AI to discover druggable targets, with similar disease-agnostic platform positioning.
  • BenevolentAI: BenevolentAI combines AI, machine learning, and biomedical knowledge graphs to accelerate drug discovery. Comparable to MultiOmic as an AI-driven drug discovery platform that identifies novel targets and partners with pharma for development.
  • Recursion Pharmaceuticals: Recursion is an AI-enabled drug discovery platform combining high-throughput biology, automated experimentation, and machine learning to identify novel therapeutic candidates. Highly comparable to MultiOmic as a techbio company building proprietary datasets and AI models to drive drug discovery, though Recursion operates at much larger scale and broader therapeutic scope.
  • BioAge Labs: BioAge Labs is an AI-driven biotech focused on metabolic disease drug discovery, using machine learning and patient data to identify targets for age-related conditions. Closely comparable to MultiOmic in therapeutic area (metabolic disease), AI approach, and stage of development.
  • Owkin: Owkin is an AI precision medicine company using federated learning and multi-omics analysis to identify biomarkers and develop diagnostics. Highly comparable to MultiOmic's multi-omics + AI approach to patient stratification and biomarker discovery, with similar B2B model selling into biopharma.

Emerging players

  • ProKidney: ProKidney is a clinical-stage biotech developing cell therapy for chronic kidney disease. Comparable therapeutic focus on CKD (MultiOmic's first indication) but uses a different modality (cell therapy vs. precision medicine/biologics) and is at later clinical stage.
  • Cardior Pharmaceuticals: Cardior Pharmaceuticals develops RNA-based therapeutics for heart failure and associated cardiac diseases, with precision medicine approaches targeting specific patient subgroups. Comparable focus on cardio-renal therapeutic area and patient stratification strategies, though at later stage with clinical assets.

Broad incumbents

  • Tempus AI: Tempus is a precision medicine data and technology company combining multi-omics profiling (genomics, transcriptomics, proteomics) with AI to enable pharma R&D and clinical decision support. Comparable to MultiOmic's data integration approach but operating at much larger scale with broader offerings and an established commercial presence.

Market position

Weaknesses4 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

MultiOmic Health social profiles

Digital presence

MultiOmic Health financial estimates

Financial estimate

Revenue estimate

Valuation estimate

MultiOmic Health leadership team

Management profile

Number of profiles

Profiles18 records

MultiOmic Health funding detail

Funding detail

Funding overview

Funding rounds3 records

Investors10 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

MultiOmic Health M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about MultiOmic Health

What does MultiOmic Health do?

MultiOmic Health develops the MOHSAIC® platform, an AI-enabled precision medicine discovery engine that integrates multi-omics data (genomics, epigenomics, transcriptomics, proteomics, metabolomics, microbiomics) with longitudinal clinical phenotyping, computational systems biology modeling, and wet laboratory validation to identify patient endotypes and discover precision therapeutic concepts. The company focuses on cardio-renal-metabolic diseases, starting with chronic kidney disease, and commercializes its outputs through biopharma partnerships, IP licensing, and collaborative R&D projects.

Is MultiOmic Health a public or private company?

MultiOmic Health is a private company. It is classified as venture growth investor backed and is currently operating.

When was MultiOmic Health founded?

MultiOmic Health was founded in 2021. It employs 11 to 50 people.

Where is MultiOmic Health based?

MultiOmic Health is headquartered in London, United Kingdom, in the Europe region.

How does MultiOmic Health make money?

Three revenue lines are on record. Value-Sharing Partnerships with Biopharma is the primary driver. The others are intellectual Property Licensing to Medtech and collaborative R&D Projects.

Who are MultiOmic Health's main competitors?

Direct peers on record are Insitro, Exscientia, Relation Therapeutics, BenevolentAI, Recursion Pharmaceuticals, BioAge Labs and Owkin. Emerging players are ProKidney and Cardior Pharmaceuticals. Tempus AI is listed as a broad incumbent.

Does MultiOmic Health have an API?

No public API is recorded for MultiOmic Health.

What industry is MultiOmic Health in?

MultiOmic Health's product category is AI Drug Discovery. Its primary akta.pro industry code is HLAAANAF, Multi-Omics Precision Medicine Platforms (genomics/proteomics/metabolomics), with a secondary code of HLAGAJAD, Bioinformatics & Multi-omics Analysis Software. Its NAICS code is 541714 and its SIC code is 8731.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
Roots AnalysisMultiomics Market Size, Share, Trends, & Insights Report, 2035A market research report forecasts the global multiomics market will grow from USD 3.10 billion in 2025 to USD 12.65 billion by 2035, driven by advancements in single-cell analysis and AI-driven data integration. Key industry participants including MultiOmic Health, Singleron Biotechnologies, and BioSkryb are actively expanding their capabilities through funding, partnerships, and new product launches to address growing demand in precision medicine and drug discovery.MultiomicMultiOmic Health and Alloy Therapeutics Collaborate to Discover and Develop Renal Tissue-Targeting DrugsMultiOmic Health Limited (MOH) and Alloy Therapeutics Inc. have signed a Memorandum of Understanding to jointly discover and develop first-in-class renal tissue-targeting drugs for chronic renal conditions, leveraging MOH's AI-enabled patient stratification and target discovery platform alongside Alloy's bispecific antibody and genetic medicine platforms. Alloy's venture studio 82VS will establish a new asset-centric drug development company (codenamed "RenalDevCo") that will license relevant intellectual property from both MOH and Alloy, with each receiving substantial equity stakes along with downstream development milestone payments and single digit royalties. MOH will also receive research services payments to oversee IND-enabling studies and manage exploratory clinical trials.LinkedInIntroducing Multiomic Health - and announcing Ada Ventures investment. We are thrilled to announce our participation in the £5m investment round in Multiomic Health https://multiomic.health/, an AI…Ada Ventures announced its participation in a £5 million investment round in Multiomic Health, an AI company focused on solutions for Metabolic Syndrome. The investment includes participation from other investors such as Hoxton Ventures and MMC Ventures, highlighting the urgent medical challenge posed by Metabolic Syndrome, which affects one in three adults globally and contributes to significant healthcare costs of $1.9 trillion annually.BitlyUK’s MultiOmic Health secures €5.7M for its AI-enabled precision drug discovery platformMultiOmic Health, a London-based company, announced it secured £5M (approximately €5.71M) in a Seed extension round of funding on May 4. This funding will be used to demonstrate proof-of-concept for its AI-enabled MOHSAIC platform in diabetic kidney disease, which targets the treatment gaps in metabolic syndrome disorders. The company aims to leverage patient data to create unique therapeutic solutions for various metabolic conditions that currently lack precision medicines.BusinessCloudAI-enabled drug discovery startup raises £5mMultiOmic Health closed a £5m seed funding extension round led by Hoxton Ventures, bringing total funding to nearly £7m. The investment will demonstrate proof-of-concept for its MOHSAIC platform in diabetic kidney disease, which affects up to 40% of diabetics and costs $300bn annually.ZapierMultiOmic Health closes $6.2 million funding round to discover precision medicines for metabolic syndrome-related conditionsMultiOmic Health has closed a £5 million seed funding extension round to advance its AI-enabled platform for discovering precision medicines targeting metabolic syndrome-related conditions. The investment was led by Hoxton Ventures with participation from Ada Ventures, MMC Ventures, and Verve Ventures, bringing the company's total raised capital to US$8.6 million since 2021. Proceeds will be used to demonstrate proof-of-concept for the MOHSAIC® platform in diabetic kidney disease.Business Wire BlogMultiOmic Health Closes $6.2 Million Funding Round to Discover Precision Medicines for Metabolic Syndrome-Related ConditionsMultiOmic Health has closed a £5 million seed funding extension round, bringing its total raised capital to US$8.6 million, to develop an AI-enabled precision therapeutics discovery platform for metabolic syndrome-related conditions. The round was led by Hoxton Ventures with participation from Ada Ventures, MMC Ventures, and Verve Ventures. Proceeds will be used to demonstrate proof-of-concept for the company's MOHSAIC® platform in diabetic kidney disease.MultiomicMultiOmic Health Closes $6.2 Million Funding Round to Discover Precision Medicines for Metabolic Syndrome-Related ConditionsMultiOmic Health has closed a £5 million (US$6.2 million) seed funding extension round to develop precision therapeutics for metabolic syndrome-related conditions. The investment was led by Hoxton Ventures, with participation from Ada Ventures, MMC Ventures, and Verve Ventures. Proceeds will be used to demonstrate proof-of-concept for the company's MOHSAIC® platform in diabetic kidney disease.Business Wire BlogMultiOmic Health Closes $6.2 Million Funding Round to Discover Precision Medicines for Metabolic Syndrome-Related ConditionsMultiOmic Health closed a £5 million (US$6.2 million) seed extension round led by Hoxton Ventures to build its precision therapeutics platform for metabolic syndrome-related conditions. The company has raised US$8.6 million since May 2021 and will use the funds to demonstrate proof-of-concept for its MOHSAIC platform in diabetic kidney disease.